Product Description
Mechanisms of Action: MTTP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Type 2 Diabetes|Obesity|Overweight
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
R256918OBE1008 | P2 |
Completed |
Obesity |
2008-10-08 |
|
CR013735 | P2 |
Completed |
Overweight|Obesity |
2008-10-01 |
|
2007-000031-26 | P2 |
Completed |
Type 2 Diabetes |
2008-09-12 |
|
R256918 | P2 |
Completed |
Type 2 Diabetes |
2008-09-01 |